INS and metabolic dysfunction-associated steatohepatitis: Thanks to their low toxicity, anti-miR-103 and anti-miR-107 (called RG-125/AZD4076 developed by Regulus Therapeutics) completed phase I clinical trials and are ongoing in phase II for the treatment of T2D, or prediabetes, with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) (http://clinicaltrials.gov—NCT02826525 and NCT02612662), by targeting insulin signaling in adipose tissue, in the liver and reducing adipocyte size.